Shots: The P-III NAVIGATOR study involves assessing Tezepelumab + SOC vs PBO +SOC in adults (18–80yrs.old) and adolescents (12–17yrs. old) with severe, uncontrolled asthma. The study showed improvements in lung […]readmore
Tags : Nasal Polyps
Shots: The US FDA has approved the sBLA for a new self-administration option for Xolair in patients across all approved indications in the US The use of the therapy across […]readmore
In a recent interview with PharmaShots, Ted Omachi, Global Development Leader for Xolair, and Senior Medical Director of Product Development for Immunology, Genentech shared his views on the approval of […]readmore
Shots: The approval is based on P-III POLYP 1 & 2 trials assessing Xolair vs PBO in 138 & 127 adult patients with nasal polyps who had an inadequate response […]readmore
Shots: The sBLA submission is based on P-III POLYP 1 & 2 studies assessing Xolair (SC) vs PBO in 138 & 127 patients with CRSwNP with inadequate response to intranasal […]readmore
Shots: The P-III POLYP 1 & POLYP 2 studies results involve assessing of Xolair (SC, q2w/q4w) vs PBO in 138 & 127 patients with CRSwNP with inadequate response to intranasal […]readmore